A directory of where to buy chemicals in the USA, including: distributors, industrial manufacturers, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the suppliers website for prices or more information.
| Product | Description | |
|---|---|---|
| MK-0493 | MK-0493 is a potent, orally active and selective agonist of the melanocortin receptor 4 (MC4R) , demonstrating significant reductions in energy intake [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 455956-93-1. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-118930. |  |
| MK-0493 Free base | MK-0493 is a novel, potent, and selective agonist of the melanocortin receptor 4 (MC4R), one of the best-validated genetic targets and considered one of the most promising for the development of antiobesity therapeutics. Uses: Undefined mechanism. Synonyms: MK0493; MK 0493; MK-0493; N-((S)-1-(2-(1-((3S,4R)-1-(tert-butyl)-4-(2,4-difluorophenyl)pyrrolidine-3-carbonyl)piperidin-4-yl)-5-chlorophenyl)ethyl)acetamide. Grades: ≥98%. CAS No. 455956-93-1. Molecular formula: C30H38ClF2N3O2. Mole weight: 546.09. |  |
| MK-0493 hydrochloride | MK-0493 hydrochloride is a potent, orally active and selective agonist of the melanocortin receptor 4 (MC4R) , demonstrating significant reductions in energy intake [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 455957-71-8. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg. Product ID: HY-118930A. | |
| MK 0524 sodium salt | MK 0524 sodium salt is a potent and selective prostaglandin D2 (PGD2) receptor 1 (DP1) antagonist with Ki values to be 0.57 nM and 750 nM for DP1 and DP2 receptors, respectively. Synonyms: MK 0524 sodium salt; MK0524 sodium salt; MK-0524 sodium salt; Laropiprant sodium; 2-[(3R)-4-[(4-chlorophenyl)methyl]-7-fluoro-5-methylsulfonyl-2,3-dihydro-1H-cyclopenta[b]indol-3-yl]acetic acid sodium. Grades: 99%. CAS No. 572874-50-1. Molecular formula: C21H18ClFNNaO4S. Mole weight: 457.88. | |
| MK0533 | MK0533 is a novel selective peroxisome proliferator-activated receptor gamma modulator. It is used for the treatment of type 2 diabetes mellitus. It reduces potential to increase plasma and extracellular fluid volume. It showed diminished maximal activity in cell-based transcription activation assays and attenuated gene signatures in adipose tissue. Uses: Mk0533 is used for the treatment of type 2 diabetes mellitus. Synonyms: MK-0533; MK 0533; (R)-2-(3-(3-(4-methoxybenzoyl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl)phenoxy)butanoic acid. Grades: 98%. CAS No. 668455-28-5. Molecular formula: C28H24F3NO6. Mole weight: 527.50. | |
| MK 0557 | MK-0557 is a highly selective, orally administered neuropeptide NPY5R antagonist, could limit weight regain after very-low-calorie diet (VLCD)-induced weight loss. Uses: Npy5r antagonist. Synonyms: MK0557; MK 0557; MK-0557; N-[1-(2-fluorophenyl)pyrazol-3-yl]-1'-oxospiro[cyclohexane-4,3'-furo[3,4-c]pyridine]-1-carboxamide. Grades: ≥98%. CAS No. 328232-95-7. Molecular formula: C22H19FN4O3. Mole weight: 406.41. | |
| MK-0591 | Quiflapon is a synthetic compound which specifically inhibits the activity of 5-Lox and is currently under development for the treatment of asthma. Also, Quiflapon, a leukotriene biosynthesis inhibitor, induces apoptosis in prostate cancer cells. Synonyms: Quiflapon; MK 591; MK-591; MK591; L 686708; L-686708; L686708; L-686,708; L 686,708; L686,708. Grades: >98%. CAS No. 136668-42-3. Molecular formula: C34H35ClN2O3S. Mole weight: 587.17. | |
| MK-0634 | MK-0634, also called as L-796568, is an β3 adrenergic receptor agonist that was progressed into clinical studies for the treatment of obesity in the early 2000s but discontinued due to unacceptable toxicity. Synonyms: MK-0634; MK 0634; MK0634; N-[4-[2-[[(2R)-2-hydroxy-2-pyridin-3-ylethyl]amino]ethyl]phenyl]-4-[4-[4-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]benzenesulfonamide; 2-hydroxy-PEAPTTB; L-796568 free base; L 796568 free base; L796568 free base; 211031-81-1 (L-796568 dihydrochloride); N-(4-(2-((2-hydroxy-2-(3-pyridinyl)ethyl)amino)ethyl)phenyl)-4-(4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)benzenesulfonamide. Grades: >98%. CAS No. 211031-01-5. Molecular formula: C31H27F3N4O3S2. Mole weight: 624.697. | |
| MK-0634 dihydrochloride | MK-0634, also called as L-796568, is an β3 adrenergic receptor agonist that was progressed into clinical studies for the treatment of obesity in the early 2000s but discontinued due to unacceptable toxicity. Uses: Adrenergic beta-3 receptor agonists. Synonyms: N-[4-[2-[[(2R)-2-hydroxy-2-pyridin-3-ylethyl]amino]ethyl]phenyl]-4-[4-[4-(trifluoromethyl)phenyl]-1, 3-thiazol-2-yl]benzenesulfonamide; dihydrochloride; L-796568 dihydrochloride; 211031-81-1 (L-796568 dihydrochloride); 211031-01-5 (L-796568 Free base); MK 0634 dihydrochloride; MK0634 dihydrochloride; MK-0634 dihydrochloride; L-796568 dihydrochloride; L 796568 dihydrochloride; L796568 dihydrochloride. Grades: >98%. CAS No. 211031-81-1. Molecular formula: C31H29Cl2F3N4O3S2. Mole weight: 697.61. | |
| MK-0668 | MK-0668 is an antagonist of very late antigen-4 with picomolar, whole blood activity and slow dissociation rates were discovered by incorporating an amino substituent on the proline fragment of the initial lead structure. Synonyms: MK0668; MK 0668; MK-0668; (S) -2- ( (2S, 4R) -1- ( (3-cyanophenyl) sulfonyl) -4- (cyclobutylamino) pyrrolidine-2-carboxamido) -3- (4- (3, 5-dichloroisonicotinamido) phenyl) propanoic acid. Grades: 98%. CAS No. 865110-07-2. Molecular formula: C31H30Cl2N6O6S. Mole weight: 685.59. | |
| MK-0668 mesylate | MK-0668 is an antagonist of very late antigen-4 with picomolar, whole blood activity and slow dissociation rates were discovered by incorporating an amino substituent on the proline fragment of the initial lead structure. Synonyms: MK0668; MK 0668; MK-0668; (S) -2- ( (2S, 4R) -1- ( (3-cyanophenyl) sulfonyl) -4- (cyclobutylamino) pyrrolidine-2-carboxamido) -3- (4- (3, 5-dichloroisonicotinamido) phenyl) propanoic acid mesylate. Grades: 98%. CAS No. 865111-04-2. Molecular formula: C31H30Cl2N6O6S.CH4O3S. Mole weight: 781.69. | |
| MK 0677 | MK 0677. Group: Biochemicals. Grades: Purified. CAS No. 159752-10-0. Pack Sizes: 10mg, 50mg. US Biological Life Sciences. |  Worldwide |
| MK0686 | MK0686 is a bradykinin B1 receptor antagonist. It exhibits suitable pharmacokinetic properties and efficient ex vivo receptor occupancy for further development as a novel approach for the treatment of pain and inflammation. It had been in phase II clinical trials by Merck Sharp & Dohme for the treatment of postherpetic neuralgia, postoperative pain and osteoarthritis. But it is discontinued now. Uses: Mk0686 is used for the treatment of postherpetic neuralgia, postoperative pain and osteoarthritis. Synonyms: MK0686; MK 0686; MK-0686;Methyl 2-chloro-6- [3-fluoro-4- [ (1R) -1- [ [1- [ (2, 2, 2-trifluoroacetyl) amino] cyclopropanecarbonyl] amino] ethyl] phenyl] benzoate; Methyl (R)-3-chloro-3'-fluoro-4'-(1-(1-(2,2,2-trifluoroacetamido)cyclopropane-1-carboxamido)ethyl)-[1,1'-biphenyl]-2-carboxyla. Grades: 98%. CAS No. 578727-68-1. Molecular formula: C22H19ClF4N2O4. Mole weight: 486.85. | |
| MK-0731 | MK-0731 is a synthetic small molecule with potential antineoplastic activity. MK0731 selectively inhibits kinesin spindle protein (KSP), which may result in the inhibition of mitotic spindle assembly, induction of cell cycle arrest during the mitotic phase, and apoptosis in tumor cells that overexpress KSP. Uses: Potential antineoplastic agent. Synonyms: ALR-3456; ALR 3456; ALR3456; 845256-65-7; MK0731, MK-0731, MK 0731; UNII-8HIJ5G3O02; 8HIJ5G3O02. CAS No. 845256-65-7. Molecular formula: C25H28F3N3O2. Mole weight: 459.513. | |
| MK-0752 | MK-0752 is a gamma secretase inhibitor in clinical development. Group: Biochemicals. Alternative Names: cis-4-[ (4-Chlorophenyl) sulfonyl]-4- (2, 5-difluorophenyl) cyclohexanepropanoic Acid. Grades: Highly Purified. CAS No. 471905-41-6. Pack Sizes: 5mg. US Biological Life Sciences. | Worldwide |
| MK-0752 | MK 0752 is a potent and reversible inhibitor of γ-secretase (IC50 ~50 nM). It was shown to reduce the number of breast cancer stem cells in tumorgrafts. Uses: Gamma secretase inhibitors and modulators. Synonyms: Cyclohexanepropanoic acid, 4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)-, cis-; cis-4-[(4-Chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropanoic acid; MK 0752; MK0752. Grades: >98%. CAS No. 471905-41-6. Molecular formula: C21H21ClF2O4S. Mole weight: 442.91. | |
| MK-0752 | MK-0752 is a moderately potent ?-secretase inhibitor, which reduces A?40 production with IC50 of 5 nM and in Phase 2. Group: Fluorinated apis. Alternative Names: cis-4-[(4-Chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropanoic acid. CAS No. 471905-41-6. Molecular formula: C21H21ClF2O4S. Mole weight: 442.9. Appearance: White to off-white solid powder. Purity: >98%. IUPACName: 3-[4-(4-chlorophenyl)sulfonyl-4-(2,5-difluorophenyl)cyclohexyl]propanoic acid. Catalog: OFC471905416. |  |
| MK-0752 sodium salt | MK-0752 sodium salt is a novel potent γ-secretase inhibitor. It is in clinical trial for treatment of several types of cancer. Uses: Mk-0752 sodium salt is used for treatment of several types of cancer. Synonyms: MK0752; MK 0752; MK-0752; MK0752 sodium salt;Sodium 3-(4-((4-chlorophenyl)sulfonyl)-4-(2,5-difluorophenyl)cyclohexyl)propanoate. Grades: 98%. CAS No. 656810-87-6. Molecular formula: C21H20ClF2NaO4S. Mole weight: 464.88. | |
| MK 0812 | MK 0812. Group: Biochemicals. Grades: Highly Purified. CAS No. 624733-88-6. Pack Sizes: 50mg, 100mg, 250mg, 500mg, 1g. US Biological Life Sciences. | Worldwide |
| MK-0812 | MK-0812 is a potent and selective CCR2 antagonist with low affinity for CCR2 on human monocytes. Synonyms: MK-0812; MK 0812; MK0812; [(1S,3R)-3-[[(3S,4S)-3-methoxyoxan-4-yl]amino]-1-propan-2-ylcyclopentyl]-[3-(trifluoromethyl)-7,8-dihydro-5H-1,6-naphthyridin-6-yl]methanone. CAS No. 624733-88-6. Molecular formula: C24H34F3N3O3. Mole weight: 469.54. | |
| MK-0822 | MK-0822 is a newly developed bone-targeting dual action pro-drug for osteoporosis and bone metastasis. It is also an inhibitor of cathepsin K, an enzyme involved in bone resorption. Group: Biochemicals. Alternative Names: N- (1-cyanocyclopropyl) -4-fluoro-N2-{ (1S) -2, 2, 2-trifluoro-1-[4'- (methylsulfonyl) biphenyl-4-yl]ethyl}-L-leucinamide, Odanacatib. Grades: Highly Purified. CAS No. 603139-19-1. Pack Sizes: 5mg. US Biological Life Sciences. | Worldwide |
| MK0873 | MK0873 is a phosphodiesterase 4 (PDE4) inhibitor. It has shown as an innovative tool to design topical formulation to achieve desired pharmacokinetics in humans along with a minipig skin biopsy model. It was developed by Merck. It was used to treat rheumatoid arthritis in phase II clinical trials and plaque psoriasis in phase I clinical trials, but it has no recent research progress. Uses: Mk0873 was used to treat rheumatoid arthritis and plaque psoriasis. Synonyms: N-cyclopropyl-1-[3-[2-(1-oxidopyridin-1-ium-3-yl)ethynyl]phenyl]-4-oxo-1,8-naphthyridine-3-carboxamide;MK0873; MK 0873; MK-0873;3-((3-(3-(cyclopropylcarbamoyl)-4-oxo-1,8-naphthyridin-1(4H)-yl)phenyl)ethynyl)pyridine 1-oxide. Grades: 98%. CAS No. 500355-52-2. Molecular formula: C25H18N4O3. Mole weight: 422.44. | |
| MK 0893 | MK-0893 is a potent, selective glucagon receptor antagonist with high binding affinity with IC(50) of 6.6 nM and functional cAMP activity with IC(50) of 15.7 nM. It is selective for glucagon receptor relative to other family B GPCRs and is > 200 fold selectivity for GIPR, PAC1, GLP-1R, VPAC1 and VPAC2. It blunted glucagon-induced glucose elevation in hGCGR mice and rhesus monkeys. It may be a potential oral treatment for type 2 diabetes. It was selected for further preclinical and clinical evaluations. Uses: Mk-0893 may be a potential oral treatment for type 2 diabetes. Synonyms: MK 0893; MK0893; MK-0893; b-Alanine, N-[4-[(1S)-1-[3-(3,5-dichlorophenyl)-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]-;Merk Glucagon antagonist;N-[4-[(1S)-1-[3-(3,5-Dichlorophenyl)-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]-beta-alanine;(S)-3-(4-(1-(3-(3,5-Dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl)ethyl)benzamido)propanoic acid. Grades: >98 %. CAS No. 870823-12-4. Molecular formula: C32H27Cl2N3O4. Mole weight: 588.48. | |
| MK0916 | MK0916 is an 11β-hydroxysteroid dehydrogenase type 1 inhibitor. It is used for patients with type 2 diabetes mellitus and metabolic syndrome and obesity-related disorders. It produces mechanism-based activation of the hypothalamic-pituitary-adrenal axis and results in mean increases in adrenal androgen levels that remains within the normal range. Uses: Mk0916 is used for patients with type 2 diabetes mellitus and metabolic syndrome and obesity-related disorders. Synonyms: MK 0916; MK-0916; 3-((1s,3s)-1-(4-chlorophenyl)-3-fluorocyclobutyl)-4,5-dicyclopropyl-4H-1,2,4-triazole. Grades: 98%. CAS No. 633317-53-0. Molecular formula: C18H19ClFN3. Mole weight: 331.82. | |
| MK 0927 | MK 0927 is a potential bio-active agent., but no detail information has been published yet. Synonyms: MK0927; MK-0927; MK 0927; 4-(2-methylpropylamino)-7,7-dioxo-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide;hydrochloride. Grades: 98%. CAS No. 126453-94-9. Molecular formula: C11H19ClN2O4S3. Mole weight: 374.91. | |
| MK-0941 mesylate | MK-0941 is a glucokinase activator used for the treatment of type II diabetes. It increases the risk of hypoglycemia and elevations in triglycerides and blood pressure. Synonyms: MK-0941; MK 0941; MK0941; 3-(6-ethylsulfonylpyridin-3-yl)oxy-5-[(2S)-1-hydroxypropan-2-yl]oxy-N-(1-methylpyrazol-3-yl)benzamide mesylate. Grades: ≥98%. CAS No. 1137916-97-2. Molecular formula: C21H24N4O6S·CH3SO3H. Mole weight: 556.61. | |
| MK-0969 | MK-0969 is an Muscarinic M3 antagonist which has the potential for the treatment of chronic obstructive pulmonary diseases. Synonyms: (2R)-N-[1-[(6-aminopyridin-2-yl)methyl]piperidin-4-yl]-2-[(1R)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetamide; MK0969; MK 0969; MK-0969; J-104135; J 104135; J104135. Grades: >98%. CAS No. 203321-88-4. Molecular formula: C24H30F2N4O2. Mole weight: 444.53. | |
| Mk1064 | Mk1064 is a selective orexin OX2 receptor antagonist for potential treatment of insomnia. Studies shows that Mk1064 could promote sleep and increase both rapid eye movement (REM) and non-REM (NREM) sleep of humans. Uses: Mk1064 is a selective orexin ox2 receptor antagonist. Synonyms: MK1064; MK 1064; MK-1064; 5''-chloro-N-[(5,6-dimethoxypyridin-2-yl)methyl]-2,2':5',3''-terpyridine-3'-carboxamide. Grades: ≥98%. CAS No. 1207253-08-4. Molecular formula: C24H20ClN5O3. Mole weight: 461.91. | |
| MK-1084 | MK-1084 is a selective KRAS G12C inhibitor that is currently in Phase I clinical trial (NCT05067283). MK-1084 exhibits anticancer activity and can be used either alone or in combination with pembrolizumab (HY-P9902) for cancer research [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 2641216-67-1. Pack Sizes: 1 mg; 5 mg. Product ID: HY-162431. | |
| MK-142 dimethanesulfonate | MK-142 is a bioactive agent with antiarrhythmic properties with its content in the skeletal muscles indicates a high affinity of the examined substance to the heart muscle. Uses: Antiarrhytmic. Synonyms: MK142; MK-142; MK 142; 3,3'-(ethane-1,2-diylbis(azanediyl))bis(1-(4-methoxyphenoxy)propan-2-ol). Grades: ≥95%. CAS No. 42794-63-8. Molecular formula: C22H32N2O6. Mole weight: 420.50. | |
| MK-1775 | MK-1775, also known as AZD-1775, is a WEE1 inhibitor and a small-molecule inhibitor of the tyrosine kinase WEE1 with potential antineoplastic sensitizing activity. MK-1775 selectively targets and inhibits WEE1, a tyrosine kinase that phosphorylates cyclin-dependent kinase 1 (CDC2) to inactivate the CDC2/cyclin B complex. Inhibition of WEE1 activity prevents the phosphorylation of CDC2 and impairs the G2 DNA damage checkpoint. This may lead to apoptosis upon treatment with DNA damaging chemotherapeutic agents. Unlike normal cells, most p53-deficient or mutated human cancers lack the G1 checkpoint as p53 is the key regulator of the G1 checkpoint and these cells rely on the G2 checkpoint for DNA repair to damaged cells. Annulment of the G2 checkpoint may therefore make p53-deficient tumor cells more vulnerable to antineoplastic agents and enhance their cytotoxic effect. Synonyms: MK-1775; MK1775; MK 1775; AZD1775; AZD-1775; AZD 1775; adavosertib. 1-[6-(2-hydroxypropan-2-yl)pyridin-2-yl]-6-[4-(4-methylpiperazin-1-yl)anilino]-2-prop-2-enylpyrazolo[3,4-d]pyrimidin-3-one. Grades: >98%. CAS No. 955365-80-7. Molecular formula: C27H32N8O2. Mole weight: 500.607. | |
| MK190 | MK190 is a synthetic bio-active chemical. Uses: A synthetic bio-active chemical. Synonyms: MK190; MK-190; MK 190; 2-(4-fluorophenyl)-1-methyl-5-nitro-1H-imidazole. Grades: ≥98%. CAS No. 4204-99-3. Molecular formula: C10H8FN3O2. Mole weight: 221.19. | |
| MK 1903 | MK 1903 is a hydroxycarboxylic acid receptor 2 (GPR109A) agonist. It may be used in the treatment of obesity and related weight disorders. Synonyms: MK 1903; MK1903; MK-1903; (4aR, 5aR)-4, 4a, 5, 5a-Tetrahydro-1H-cyclopropa[4, 5]cyclopenta[1, 2]pyrazole-3-carboxylic acid. Grades: ≥98% by HPLC. CAS No. 1268882-43-4. Molecular formula: C8H8N2O2. Mole weight: 164.16. | |
| MK 1903 | MK 1903. Group: Biochemicals. Grades: Purified. CAS No. 1268882-43-4. Pack Sizes: 10mg, 50mg. US Biological Life Sciences. | Worldwide |
| MK 1-907 | MK-1-907 is a centrally acting drug, but no detailed information has been published yet. Uses: Centrally acting drug. Synonyms: MK1907; MK-1-907; MK-1907; MK1-907; MK-1-907; 3- ( (3-methoxyphenyl)amino)-5, 5-dimethyl-2- ( (methyl (phenethyl)amino)methyl)cyclohex-2-en-1-one. Grades: 98%. CAS No. 78150-06-8. Molecular formula: C25H32N2O2. Mole weight: 392.54. | |
| MK-2048 | MK-2048 is a second generation integrase inhibitor (IC50=2.6 nM). It can inhibits the HIV enzyme integrase 4 times longer than raltegravir. Synonyms: MK2048; MK 2048; MK-2048. Grades: >98%. CAS No. 869901-69-9. Molecular formula: C22H24FN5O4. Mole weight: 441.46. | |
| MK-2048 | MK-2048 represents a prototype second generation integrase strand transfer inhibitor (INSTI), it was developed with the goal of retaining activity against viruses containing mutations assiciated with resistance of first-generation INSTIs, raltegravir. MK-2048 exhibits inhibitory activity towards HIV integrase and towards HIV replication. It is four times more effective in inhibiting HIV enzyme integrase than the first generation inhibitor, raltegravir. Group: Biochemicals. Alternative Names: (6S)-2-(3-Chloro-4-fluorobenzyl)-8-ethyl-10-hydroxy-N, 6-dimethyl-1, 9-dioxo-1, 2, 6, 7, 8, 9-hexahydropyrazino[1', 2':1, 5]pyrrolo[2, 3-d]pyridazine-4-carboxamide. Grades: Highly Purified. CAS No. 869901-69-9. Pack Sizes: 5mg. US Biological Life Sciences. | Worldwide |
| MK212 | MK212 is a 5HT2C-receptor agonist. It exhibited anxiolytic activity in mice at low doses. It is a serotonin agonist. It could promote the secretion of serum prolactin and cortisol in humans. Uses: Mk212 exhibites anxiolytic activity and could promote the secretion of serum prolactin and cortisol in humans. Synonyms: MK212; MK 212; MK-212; 2-Chloro-6-(1-piperazinyl)pyrazine;MK-212;2-Chloro-6-(piperazin-1-yl)pyrazine. Grades: 98%. CAS No. 64022-27-1. Molecular formula: C8H11ClN4. Mole weight: 198.65. | |
| MK 212 hydrochloride | MK 212 hydrochloride. Group: Biochemicals. Grades: Purified. CAS No. 61655-58-1. Pack Sizes: 10mg, 50mg. US Biological Life Sciences. | Worldwide |
| MK212 hydrochloride | MK212 hydrochloride is a selective 5-HT2C serotonin receptor agonist. It displays selectivity for 5-HT2C over 5-HT2A with IC50 values of 0.028 and 0.42 μM for human 5-HT2C and 5-HT2A receptors expressed in HEK293 cells respectively. Uses: Serotonin receptor agonists. Synonyms: MK212; MK 212; MK-212; MK-212 hydrochloride;1-(6-Chloro-2-pyrazinyl)piperazine monohydrochloride;2-Chloro-6-(1-piperazinyl)pyrazine monohydrochloride. Grades: 98%. CAS No. 61655-58-1. Molecular formula: C8H12Cl2N4. Mole weight: 235.11. | |
| MK-2206 | MK-2206 Inhibitor. Uses: Scientific use. Product Category: T1952. CAS No. 1032350-13-2. |  |
| MK-2206 | MK-2206 is an orally active, highly potent and selective allosteric Akt inhibitor, with IC 50 s of 8, 12, and 65 nM for Akt1, Akt2, and Akt3, respectively. Many breast cancer cell lines, and PIK3CA-mutant and cell lines with PTEN loss are sensitive to MK-2206. MK-2206 has anticancer activities [1] [2]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1032349-77-1. Pack Sizes: 5 mg; 10 mg. Product ID: HY-108232. | |
| MK-2206 | MK-2206 is an allosteric inhibitor of Akt that prevents translocation of Akt to membranes. It is also an orally bioavailable allosteric inhibitor of the serine/threonine protein kinase Akt (protein kinase B). It binds to and inhibits the activity of Akt in a non-ATP competitive manner, which may result in the inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis. It has potential antineoplastic activity. It exhibits anticancer chemotherapeutic activity in a variety of in vitro cancer models. It induces G1-phase cell cycle arrest in hepatocellular carcinoma cells, inhibits cell proliferation in non-small cell lung cancer cells, and inhibits proliferation in medullary thyroid cancer cells. It also inhibits tumor growth in animal models of nasopharyngeal cancer. It was developed by Merck Sharp & Dohme and in clinic phase 2 trials. Uses: Mk-2206 has potential antineoplastic activity. Synonyms: MK2206; MK 2206; MK-2206; 8-(4-(1-Aminocyclobutyl)phenyl)-9-phenyl-8,9-dihydro-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3(2H)-one;8-[4-(1-Aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one. Grades: 95%. CAS No. 1032349-93-1. Molecular formula: C25H21N5O. Mole weight: 407.47. | |
| MK-2206 (8-(4-(1-Aminocyclobutyl)phenyl-9-phenyl[1, 2, 4]triazolo[3, 4-f][1, 6]naphthyridin-3(2H)-one Dihydrochloride) | A highly selective non-ATP competitive allosteric Akt inhibitor with IC??s of 8nM, 2nM and 65nM for Akt1, Akt2 and Akt3, respectively. MK-2206 potently inhibits phosphorylation of Thr308 and Ser473 in 3T3-L1 adipocytes with IC?? values of 0.11 and 0.18uM, respectively as well as downstream effects of insulin on GLUT4 translocation (IC?? = 0.47uM) and glucose transport (IC?? = 0.14uM). In addition, treatment with MK-2206 causes a robust, concentration-dependent activation of autophagy in human glioma cell lines LN229 and T98G. Group: Biochemicals. Grades: Highly Purified. CAS No. 1032350-13-2. Pack Sizes: 500ug, 1mg. US Biological Life Sciences. | Worldwide |
| MK-2206 dihydrochloride | MK-2206 dihydrochloride. Group: Biochemicals. Alternative Names: 8-[4- (1-Aminocyclobutyl) phenyl]-9-phenyl-1, 2, 4-triazolo[3, 4-f][1, 6]naphthyridin-3 (2H) -one hydrochloride. Grades: Highly Purified. CAS No. 1032350-13-2. Pack Sizes: 25mg, 50mg, 100mg, 250mg, 500mg. Molecular Formula: C25H23Cl2N5O. US Biological Life Sciences. | Worldwide |
| MK-2206 dihydrochloride | MK-2206 is a highly selective Akt inhibitor with IC50 of 8 nM, 12 nM and 65 nM for Akt1, Akt2 and Akt3, respectively. It is undergoing a phase II clinical trial for the treatment of ovarian, fallopian tube, or primary peritoneal cancer where there are mutations in P13K or AKT or low levels of PTEN. Synonyms: MK-2206. MK 2206. MK2206. Grades: >98%. CAS No. 1032350-13-2. Molecular formula: C25H23Cl2N5O. Mole weight: 480.4. | |
| MK-2206 dihydrochloride | MK-2206 dihydrochloride (MK-2206 (2HCl)) is an orally active, BBB-penetrated allosteric AKT inhibitor with IC 50 s of 5 nM, 12 nM, and 65 nM for AKT1 , AKT2 , and AKT3 , respectively. MK-2206 dihydrochloride induces autophagy [1] [2]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: MK-2206 (2HCl). CAS No. 1032350-13-2. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg; 200 mg; 500 mg. Product ID: HY-10358. | |
| MK-2206 hydrochloride | MK-2206 hydrochloride is the hydrochloride form of MK-2206, which is an allosteric inhibitor of Akt and an orally bioavailable allosteric inhibitor of the serine/threonine protein kinase Akt (protein kinase B). It has potential antineoplastic activity. It exhibits anticancer chemotherapeutic activity in a variety of in vitro cancer models. It inhibits tumor growth in animal models of nasopharyngeal cancer. Uses: Mk-2206 hydrochloride has potential antineoplastic activity. Synonyms: MK-2206 hydrochloride; MK 2206 hydrochloride; 8-[4-(1-Aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one hydrochloride;MK2206 hydrochloride. Grades: >98 %. CAS No. 1032349-77-1. Molecular formula: C25H22ClN5O. Mole weight: 443.93. | |
| MK-2295 | MK-2295 is a potent TRPV1 antagonist. TRPV1 antagonists has the potential as analgesic and anti-inflammatory agents. Synonyms: MK-2295; MK 2295; MK2295; 6-[(3R)-4-[6-(4-fluorophenyl)-2-[(2R)-2-methylpyrrolidin-1-yl]pyrimidin-4-yl]-3-methylpiperazin-1-yl]-5-methylpyridine-3-carboxylic acid; 6-{4-[6-(4-Fluoro-phenyl)-2-(2-methyl-pyrrolidin-1-yl)-pyrimidin-4-yl]-3-(R)-methyl-piperazin-1-yl}-5-methyl-nicotinic acid; 3-Pyridinecarboxylic acid, 6-[(3R)?-4-[6-(4-fluorophenyl)?-2-[(2R)?-2-methyl-1-pyrrolidinyl]?-4-pyrimidinyl]?-3-methyl-1-piperazinyl]?-5-methyl-; 878811-00-8 (free base); 1855897-95-8 (mesylate salt). Grades: >98%. CAS No. 878811-00-8. Molecular formula: C27H31FN6O2. Mole weight: 490.58. | |
| MK-2461 | MK-2461 is a novel ATP-competitive multitargeted inhibitor of activated c-Met. MK-2461 inhibited in vitro phosphorylation of a peptide substrate recognized by wild-type or oncogenic c-Met kinases (N1100Y, Y1230C, Y1230H, Y1235D, and M1250T) with IC50 values of 0.4 to 2.5 nmol/L. In tumor cells, MK-2461 effectively suppressed constitutive or ligand-induced phosphorylation of the juxtamembrane domain and COOH-terminal docking site of c-Met, and its downstream signaling to the phosphoinositide 3-kinase-AKT and Ras-extracellular signal-regulated kinase pathways, without inhibiting autophosphorylation of the c-Met activation loop. In cell culture, MK-2461 inhibited hepatocyte growth factor/c-Met-dependent mitogenesis, migration, cell scatter, and tubulogenesis. In a murine xenograft model of c-Met-dependent gastric cancer, a well-tolerated oral regimen of MK-2461 administered at 100 mg/kg twice daily effectively suppressed c-Met signaling and tumor growth. Synonyms: MK 2461; MK2461; MK-2461. Grades: >98%. CAS No. 917879-39-1. Molecular formula: C24H25N5O5S. Mole weight: 495.554. | |
| MK-251 | MK-251 is a synthetic bio-active chemical. Uses: A synthetic bio-active chemical. Synonyms: MK 251; MK251; alpha,alpha-Dimethyl-4-(alpha,alpha,beta,beta-tetrafluorophenethyl)benzylamine. Grades: ≥98%. CAS No. 40396-83-6. Molecular formula: C17H17F4N. Mole weight: 311.32. | |
| MK 287 | MK-287 is platelet activating factor (PAF) inhibitor originated by Merck & Co. It can potently inhibit [3H]C18-PAF binding to human platelet, PMN (polymorphonuclear leukocyte) and lung membranes. The inhibitory effects are competitive and stereospecific. Clinical trials for asthma was discontinued. Uses: Asthma. Synonyms: MK-287; MK 287; MK287; L-680573; L 680573; L680573;2-((3-methoxy-2-propoxy-5-((2S,5S)-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran-2-yl)phenyl)sulfonyl)ethan-1-ol. Grades: 98%. CAS No. 135947-75-0. Molecular formula: C25H34O9S. Mole weight: 510.60. | |
| MK-2894 | MK-2894, a nonacylsulfonamide analogue, is a high affinity full antagonist against the EP4 receptor. It is found to have conceivable potency and selectivity for further study and might be safer than traditional Non-steroidal anti-inflammatory drugs and co. Uses: Mk-2894, a nonacylsulfonamide analogue, is a high affinity full antagonist against the ep4 receptor. Synonyms: MK-2894; MK 2894; MK2894; CHEMBL597997; 1006036-87-8; 4- [1- [ [2, 5-dimethyl-4- [ [4- (trifluoromethyl) phenyl] methyl] thiophene-3-carbonyl] amino] cyclopropyl] benzoicacid; C25H22F3NO3S; GTPL4041. Grades: 95%. CAS No. 1006036-87-8. Molecular formula: C25H22F3NO3S. Mole weight: 473.51. | |
| MK-2894 Na salt | The sodium salt form of MK-2894 that is found to have conceivable potency and selectivity for further study and might be safer than traditional Non-steroidal anti-inflammatory drugs and coxibs in the treatment of pain and inflammation. IC50: 2.5 nM (Ki=0. Uses: The sodium salt form of mk-2894 that is found to have conceivable potency and selectivity in the treatment of pain and inflammation. Synonyms: MK-2894 Na salt; MK 2894 Na salt; MK2894 Na salt; sodium; 4-[1-[[2, 5-dimethyl-4-[[4- (trifluoromethyl) phenyl]methyl]thiophene-3-carbonyl]amino]cyclopropyl]benzoate; MK-2894 (sodiumsalt) ; 1006036-88-9; MK-2894Nasalt; C25H21F3NO3S. Na. Grades: 95%. CAS No. 1006036-88-9. Molecular formula: C25H21F3NNaO3S. Mole weight: 495.49. | |
| MK-2 Dye | MK-2 Dye. Group: Organic solar cell (opv) materials. CAS No. 1037440-21-3. Product ID: (Z)-2-cyano-3-[5-[5-[5-[5-(9-ethylcarbazol-3-yl)-3-hexylthiophen-2-yl]-3-hexylthiophen-2-yl]-3-hexylthiophen-2-yl]-3-hexylthiophen-2-yl]prop-2-enoic acid. Molecular formula: 955.5g/mol. Mole weight: C58H70N2O2S4. CCCCCCC1=C (SC (=C1) C2=C (C=C (S2) C3=C (C=C (S3) C4=C (C=C (S4) C5=CC6=C (C=C5) N (C7=CC=CC=C76) CC) CCCCCC) CCCCCC) CCCCCC) C=C (C#N) C (=O) O. InChI=1S / C58H70N2O2S4 / c1-6-11-15-19-25-40-34-52 (63-50 (40) 38-45 (39-59) 58 (61) 62) 55-43 (27-21-17-13-8-3) 36-54 (65-55) 57-44 (28-22-18-14-9-4) 37-53 (66-57) 56-42 (26-20-16-12-7-2) 35-51 (64-56) 41-31-32-49-47 (33-41) 46-29-23-24-30-48 (46) 60 (49) 10-5 / h23-24, 29-38H, 6-22, 25-28H2, 1-5H3, (H, 61, 62) / b45-38-. FOELOZKDLHJOHT-JYRXYQGCSA-N. |  |
| MK2-IN-1 | MK2-IN-1, a selective MAPKA-PK2 inhibitor, could probably influence the formation of proinflammatory cytokines. IC50: 0.11 uM. Uses: Mk2-in-1 is a selective mapka-pk2 inhibitor that could probably influence the formation of proinflammatory cytokines. Synonyms: MK2 Inhibitor. Grades: 98%. CAS No. 1314118-92-7. Molecular formula: C27H25ClN4O2. Mole weight: 472.97. | |
| MK2-IN-1 hydrochloride | The hydrochloride salt form of MK2-IN-1 which is a selective MAPKA-PK2 inhibitor and could probably influence the formation of proinflammatory cytokines. IC50: 0.11 uM. Uses: The hydrochloride salt form of mk2-in-1 which is a selective mapka-pk2 inhibitor and could probably influence the formation of proinflammatory cytokines. Synonyms: MK25; MK-25; MK 25; MK2 Inhibitor IV; MK2 Inhibitor-IV; MK2 Inhibitor. Grades: 98%. CAS No. 1314118-94-9. Molecular formula: C27H26Cl2N4O2. Mole weight: 509.43. | |
| MK2 Inhibitor III | MK2 inhibitor III is a cell-permeable and ATP-competitive inhibitor of mitogen-activated protein kinase-activated protein kinase 2 (MAPKAP-K2 or MK-2). It was shown to block LPS-induced synthesis of TNF-α in human monocyte-like U937 cells with IC50 value of 4.4 μM. Synonyms: 2-(2-(Quinolin-3-yl)pyridin-4-yl)-6,7-dihydro-1H-pyrrolo[3,2-c]pyridin-4(5H)-one hydrate. Grades: ≥95%. CAS No. 1186648-22-5. Molecular formula: C21H16N4O·H2O. Mole weight: 358.4. | |
| MK-2 Inhibitor IV, MK-25 (MAPKAP-K2 Inhibitor IV, MK-25, 5-(4-Chlorophenyl)-N-(4-(piperazin-1-yl)phenyl)-N-(pyridin-2-ylmethyl)furan-2-carboxamide, HCl) | A cell-permeable furanylcarboxamide compound that acts as a potent, reversible and non-ATP-competitive inhibitor of MK-2/MAPKAP-K2 activity (IC50=110nM; EC50=350nM for pHSP27 in IL-1b-stimulated SW1353 cells) with excellent selectivity over 150 kinases (% activity inhibition at 10uM against human CK2, Haspin, Arg and CK1y3=40, 40, 42 and >70, respectively). Shown to efficiently suppress the secretions of TNFa, IL6 (IC50=4.4 and 5.2uM in LPS-stimulated THP1 cell, respectively) and MMP-13 (IC50=5.7 and 2.2uM in IL1b-stimulated SW1353 and in primary osteoarthritis-derived chondrocytes, respectively). Exhibits desirable bioavailability and weakly inhibits a panel of cytochrome P450 isozymes (IC50>20uM for 3A4, 2D6 and 2C9). Group: Biochemicals. Grades: Highly Purified. Pack Sizes: 10mg. US Biological Life Sciences. | Worldwide |
| MK-3207 | MK-3207 is an orally active, highly selective and species-specific CGRP receptor antagonist (for human CGRP receptor : IC 50 =0.12 nM; K i =0.024 nM). MK-3207 can be used for migraine studies [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 957118-49-9. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg. Product ID: HY-10301. | |
| MK-3207 | MK-3207 is a orally active and potent calcitonin gene-related peptide (CGRP) receptor antagonist IC50 vaule of 0.12 nM and Ki value of 0.024 nM. It is highly selective versus human AM1, AM2, CTR, and AMY3. It displays lower affinity for human CGRP receptors from other species, including canine and rodent. It is a potent antagonist of the human and rhesus monkey CGRP receptors in vitro. It produced a concentration-dependent inhibition of dermal vasodilation in vivo. It is effective acute migraine treatments. It was developed by Merck & Co., Inc. and was terminated in clinic phase 2. Uses: Mk-3207 is effective acute migraine treatments. Synonyms: MK3207; MK 3207; MK-3207; 2-[(8R)-8-(3,5-difluorophenyl)-10-oxo-6,9-diazaspiro[4.5]decan-9-yl]-N-[(2R)-2'-oxospiro[1,3-dihydroindene-2,3'-1H-pyrrolo[2,3-b]pyridine]-5-yl]acetamide;(8R)-8-(3,5-Difluorophenyl)-10-oxo-N-[(2R)-1,1',2',3-tetrahydro-2'-oxospirv [4.5]decane-9-acetamide;6,9-Diazaspiro[4.5]decane-9-acetaMide,8-(3,5-difluorophenyl)-10-oxo-N-[(2R)-1,1',2',3-tetrahydro-2'-oxospiro[2H-indene-2,3'-[3H]pyrrolo[2,3-b]pyridin]-5-yl]-,(8R)-. Grades: >98 %. CAS No. 957118-49-9. Molecular formula: C31H29F2N5O3. Mole weight: 557.59. | |
| MK-3207 HCl | MK-3207 is a potent CGRP receptor antagonist with IC50 and Ki of 0.12 nM and 0.022 nM, highly selective versus human AM1, AM2, CTR, and AMY3. Synonyms: MK-3207 HCl; MK 3207 HCl; MK3207 HCl. Grades: >98%. CAS No. 957116-20-0. Molecular formula: C31H29F2N5O3·HCl. Mole weight: 594.05. | |
| MK-3207 Hydrochloride | MK-3207 (Hydrochloride) is a potent and orally bioavailable CGRP receptor antagonist with IC 50 of 0.12 nM and K i of 0.024 nM, and is highly selective versus human AM1, AM2, CTR, and AMY3. Uses: Scientific research. Group: Signaling pathways. CAS No. 957116-20-0. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg. Product ID: HY-10302. | |
| MK-3328 | This molecular has a favorable potency versus human β-amyloid plaque and has been radiolabeled for further evaluation in in vitro binding and in vivo PET imaging experiments. Studies led to the identification of MK-3328 as a candidate PET ligand for the clinical assessment of β-amyloid plaque load. In Aug 2009, Phase-I clinical trials in Alzheimer's disease in Belgium was on-going, but no recent reported has been published yet. Uses: Alzheimer's disease. Synonyms: MK3328; MK 3328; MK-3328; 5-fluoro-2-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)oxazolo[5,4-b]pyridine. Grades: 98%. CAS No. 1201323-97-8. Molecular formula: C14H9FN4O. Mole weight: 268.25. | |
| MK-351 hydrochloride | MK-351 hydrochloride is an alpha-adrenergic agonist selective for α2-adrenergic receptors. It is a psychoactive drug used as a sympatholytic or antihypertensive. It plays a role in treating hypertension and gestational hypertension. It has a dual mechanism of action. It is a competitive inhibitor of the enzyme DOPA decarboxylase, which converts L-DOPA into dopamine. It is converted to α-methylnorepinephrine by dopamine beta-hydroxylase. Uses: Mk-351 hydrochloride is a psychoactive drug used as a sympatholytic or antihypertensive. it plays a role in treating hypertension and gestational hypertension. Synonyms: MK-351 hydrochloride; MK 351 hydrochloride; MK351 hydrochloride; Alpha-Methyldopa hydrochloride;L-(-)-A-Methyldopa hydrochloride;Alpha-Methyldopa HCl;(2S)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;3-Hydroxy-alpha-methyl-L-tyrosine hydrochloride;L-Tyrosine, 3-hydroxy-alpha-methyl-, hydrochloride;Methyldopa hydrochloride. Grades: >98 %. CAS No. 884-39-9. Molecular formula: C10H14ClNO4. Mole weight: 247.68. | |
| MK-3697 | MK3697 is a highly potent, orally bioavailable selective orexin 2 receptor antagonists (2-SORAs) that possess acceptable profiles for clinical development. MK-3697 is also the third insomnia product, currently being developed by Merck. MK-3697 has Ki = 0.95 nM. Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. In vivo tests results on MK-3697 demonstrated improved stability and TDI profiles as well as excellent sleep efficacy across species. Synonyms: MK-3697; MK3697; MK 3697. Grades: 0.99. CAS No. 1224846-01-8. Molecular formula: C23H21N5O3S. Mole weight: 447.513. | |
| MK-386 | MK-386 is a human type I 5α-reductase inhibitor with selectivity for type I 5α-reductase over type II 5α-reductase (IC50 = 0.9 and 154 nM, respectively). It reduces dihydrotestosterone (DHT) in serum and sebum in a dose-dependent manner, suggesting its utilization in acne treatment. Uses: 5-alpha reductase inhibitors. Synonyms: MK 386; MK386; (4aR,4bS,6aR,7R,9aS,9bS,10S,11aR)-7-[(1R)-1,5-Dimethylhexyl]hexadecahydro-1,4a,6a,10-tetramethyl-2H-indeno[5,4-f]quinolin-2-one. Grades: ≥98% by HPLC. CAS No. 158493-17-5. Molecular formula: C28H49NO. Mole weight: 415.69. | |
| MK-3903 | MK-3903 is a potent and selective AMPK activator with EC50 value of 8 nM. Synonyms: MK 3903; MK3903; 5-[[6-Chloro-5-(4-phenylphenyl)-1H-benzimidazol-2-yl]oxy]-2-methylbenzoic acid. CAS No. 1219737-12-8. Molecular formula: C27H19ClN2O3. Mole weight: 454.90. | |
| MK-3984 | MK-3984 is a androgen receptor modulators. It can be used for the prevention and treatment of muscle wasting associated with cancer. Uses: Muscle wasting associated with cancer. Synonyms: MK3984; MK 3984; MK-3984; (R)-3,3,3-trifluoro-N-(2-fluoro-5-(trifluoromethyl)benzyl)-2-hydroxy-2-phenylpropanamide. Grades: 98%. CAS No. 871325-55-2. Molecular formula: C17H12F7NO2. Mole weight: 395.27. | |
| MK 410 | MK 410 is an anti-inflammatory drug which can induce alterations in the immune system by the suppression of plasma neutral proteinase activity. Uses: Anti-inflammatory. Synonyms: MK-410; MK 410; MK410; 2-(5-methoxy-2-methyl-1-(4-(methylthio)benzyl)-1H-indol-3-yl)propanoic acid. Grades: ≥98%. CAS No. 40738-05-4. Molecular formula: C21H23NO3S. Mole weight: 369.47. | |
Our database is helping our users find suppliers everyday.
